1. Home
  2. JWEL vs APM Comparison

JWEL vs APM Comparison

Compare JWEL & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jowell Global Ltd.

JWEL

Jowell Global Ltd.

HOLD

Current Price

$2.30

Market Cap

5.7M

ML Signal

HOLD

Logo Aptorum Group Limited

APM

Aptorum Group Limited

HOLD

Current Price

$0.78

Market Cap

6.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JWEL
APM
Founded
2012
2010
Country
China
United Kingdom
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
6.8M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
JWEL
APM
Price
$2.30
$0.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.8K
262.1K
Earning Date
05-12-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.47
$0.65
52 Week High
$3.00
$4.47

Technical Indicators

Market Signals
Indicator
JWEL
APM
Relative Strength Index (RSI) 46.54 39.42
Support Level $2.29 $0.76
Resistance Level $2.45 $0.89
Average True Range (ATR) 0.12 0.10
MACD -0.01 -0.02
Stochastic Oscillator 38.18 0.62

Price Performance

Historical Comparison
JWEL
APM

About JWEL Jowell Global Ltd.

Jowell Global Ltd is a cosmetics, health, nutritional supplements, and household products e-commerce platform in China. The company offers its branded products to customers and also sells and distributes products from other companies on its platform. In addition, it allows third parties to open their stores on its platform for a service fee based on their sales revenues generated from their online stores and provides them with information about market needs, enabling them to manage their sales effort, as well as an effective platform to promote their brands. The company currently operates under four sales channels: Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing.

About APM Aptorum Group Limited

Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.

Share on Social Networks: